Florida / New York

Ph: 561.316.3330

A Publication for the Practicing Medical Specialist, Industry Executive & Investor

CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

View the latest clinical trials, studies, data, and updates.

Oncolytics Biotech Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO

“The data from this study show a correlation between the expansion of TIL-specific clones and tumor response, which provides compelling support for the use of pelareorep-based therapies in immunologically “cold” tumors. In particular, these data, along with the impressive clinical results, support the ability of pelareorep-checkpoint inhibitor combination therapies to meaningfully improve treatment responses in diseases like pancreatic cancer that have resisted immune-based therapeutic approaches,” said Thomas Heineman, M.D., Ph.D., Chief Medical Officer at Oncolytics Biotech.

Read More »

New Phase 3 TREMFYA® (guselkumab) Results in Ulcerative Colitis Show a 77 Percent Overall Clinical Response Rate and Early Symptom Improvement

“Ulcerative colitis is a complex immune-mediated disease that can cause a wide range of often-debilitating symptoms,” said study author Jessica R. Allegretti, M.D., Medical Director, Crohn’s and Colitis Center at the Brigham and Women’s Hospital, Boston, MA, USA.c “Results from the QUASAR studies support the potential of TREMFYA as a durable and fast-acting treatment option.”

Read More »

NICO Corporation Awards $40,000 Grant to London’s Kings College Hospital

To assess differences in the microstructural improvement of brain fiber tracts between Minimally Invasive Parafascicular Surgery (MIPS) with NICO’s BrainPath and a conventional surgical approach following deep-seated tumor removal. The study aims to correlate these differences with associated clinical repercussions and patient functional outcomes that ultimately impact treatment decisions.

Read More »